Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.35 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.35 |
| ▸ | TOP2A | P11388 | 2/20 | 0.33 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.32 |
| ▸ | TUBB | P07437 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30138591 | 1.00 | LMNA (0.43) | LMNAKDM4EPOLBMAPTCA12 | |
| SCHEMBL30841804 | 0.89 | KDM4E (0.42) | LMNAKDM4EPOLBMAPTCA12 | |
| SCHEMBL22200929 | 0.89 | LMNA (0.42) | LMNAKDM4EPOLBMAPTCA12 | |
| SCHEMBL37106799 | 0.89 | LMNA (0.42) | LMNAKDM4EPOLBMAPTCA12 | |
| SCHEMBL7165490 | 0.89 | LMNA (0.42) | LMNAKDM4EPOLBMAPTCA12 | |
| SCHEMBL25374762 | 0.88 | POLB (0.44) | LMNAKDM4EPOLBMAPTCA12 | |
| SCHEMBL30841546 | 0.85 | LMNA (0.47) | LMNAKDM4EPOLBMAPTCRBN | |
| SCHEMBL7657382 | 0.85 | CRBN (0.34) | LMNAKDM4ECRBNRAB9A | |
| SCHEMBL24728325 | 0.84 | LMNA (0.42) | LMNAKDM4EPOLBMAPTCA12 | |
| SCHEMBL7653009 | 0.83 | LMNA (0.46) | LMNAKDM4EPOLBMAPTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2026-05-28 | — | — | US | disclosed |
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | BIO THERA SOLUTIONS LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2025-10-30 | — | — | US | disclosed |
| US-20250262316-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2025-08-21 | — | — | US | disclosed |
| US-20250249114-A1 | METHOD FOR TREATING HER2-POSITIVE SOLID TUMOR | BIO-THERA SOLUTIONS, LTD. (CN) | 2025-08-07 | — | — | US | disclosed |
| EP-4556027-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | Bio-Thera Solutions, Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| EP-4545099-A1 | METHOD FOR TREATING SOLID TUMOR | Bio-Thera Solutions, Ltd. (CN) | 2025-04-30 | — | — | EP | disclosed |
| EP-4538291-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Bio-Thera Solutions, Ltd. (CN) | 2025-04-16 | — | — | EP | disclosed |
| EP-4534105-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Bio-Thera Solutions, Ltd. (CN) | 2025-04-09 | — | — | EP | disclosed |
| CN-116898986-A | Methods of treating HER2 positive solid tumors | 百奥泰生物制药股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023116911-A1 | ANTI-FRα ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 百奥泰生物制药股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116911-A1 | ANTI-FRα ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 百奥泰生物制药股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| CN-116333135-A | anti-FR alpha antibody, antibody drug conjugate and application thereof | 百奥泰生物制药股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2023061457-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | 百奥泰生物制药股份有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2023061457-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | 百奥泰生物制药股份有限公司 | 2023-04-20 | — | — | WO | disclosed |
| CN-115969996-A | Antibody drug conjugates and uses thereof | 百奥泰生物制药股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2022253284-A1 | DRUG CONJUGATE AND USE THEREOF | 百奥泰生物制药股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253284-A1 | DRUG CONJUGATE AND USE THEREOF | 百奥泰生物制药股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| CN-115429893-A | Drug conjugates and uses thereof | 百奥泰生物制药股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | NECTIN4, VSIG8, IGSF11 | LMNA 4407/4885KDM4E 1440/4885POLB 4251/4885 |
| US-20250249114-A1 | METHOD FOR TREATING HER2-POSITIVE SOLID TUMOR | ERBB2, EGFR, ERBB3 | LMNA 4363/4885KDM4E 3617/4885POLB 3254/4885 |
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | NECTIN4, CD22, NGFR | LMNA 2062/4885KDM4E 4366/4885POLB 4692/4885 |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | CNTN1, EPCAM, SLC22A8 | LMNA 1502/4885KDM4E 2741/4885POLB 4442/4885 |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | TPM4, TPM3, TPST2 | LMNA 3733/4885KDM4E 4103/4885POLB 3790/4885 |
| US-20250262316-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | FCGR2A, FCGR1A, FCGR3B | LMNA 3657/4885KDM4E 2333/4885POLB 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.